The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which novel agents will benefit frail patients?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Alessandra Larocca, City of Health and Science University Hospital, Turin, IT. We asked, Which novel agents will benefit frail patients? 

Which novel agents will benefit frail patients?

In this video,  Larocca highlights novel agents that are well tolerated across all patients but mentions the need for adjusting treatments to balance tolerability and efficacy in frail patients.

Share:
More about...